AbbVie is watching competitors to top seller Humira come up the pipeline at several of its Big Pharma peers. And now, one of those competitors topped the rheumatoid arthritis behemoth in a late-stage trial.
Sanofi and Regeneron, awaiting FDA approval for a potential blockbuster rheumatoid arthritis treatment, burnished the drug's profile with Phase III data showing it beat AbbVie's top-selling Humira head to head.
Sanofi's biotech unit Genzyme is recalling more than 36,000 vials of its thyroid cancer drug Thyrogen from the U.S., Puerto Rico and four other countries. Thyrogen is one of a several drugs that had been in short supply some years back after Genzyme ran into manufacturing issues.
Sanofi announced that Novartis vet Ameet Nathwani has been named EVP and group chief medical officer, earning a seat on the executive committee.
Sanofi Pasteur MSD, the European vaccines joint venture between pharma giants Sanofi and Merck, has been around for 22 years. But now, the pair has decided that's long enough.
Just weeks after Bloomberg reported that Sanofi's new CEO, Olivier Brandicourt, was mulling over the fate of its 20-year-old European joint vaccine development and commercialization venture with Merck, the two pharma giants have agreed to call it quits.
One word popped up over and over when Big Pharma reported earnings last month: Venezuela. The association wasn't positive. Executives blamed losses there for hundreds of millions in currency-related hits to their financials.
Just last month, Sanofi became the first Big Pharma player to enter the Zika vaccine R&D; space as its peers calculated their responses and weighed their options. Now, the French pharma is taking it a step further, outlining its plans to devote dozens of scientists to the field in a move aimed at expediting its vaccine development.
Zealand Pharma's danegaptide has missed the primary endpoint in a Phase II cardiac reperfusion injury trial. The failure of the study, which was viewed as a long shot by some analysts, has led to Zealand focusing its resources on other areas of its pipeline.
Breaking up can be hard to do, Sanofi's Olivier Brandicourt is finding out about the company's European generics unit. As part of his plan to refocus the company, the new CEO said last year he would consider a divestiture of the unit but sources are saying the French drugmaker is having difficulty deciding how to make that happen.